Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases

被引:123
|
作者
Marcotte, Douglas J. [1 ]
Liu, Yu-Ting [1 ]
Arduini, Robert M. [1 ]
Hession, Catherine A. [1 ]
Miatkowski, Konrad [1 ]
Wildes, Craig P. [1 ]
Cullen, Patrick F. [1 ]
Hong, Victor [1 ]
Hopkins, Brian T. [1 ]
Mertsching, Elisabeth [2 ]
Jenkins, Tracy J. [1 ]
Romanowski, Michael J. [3 ]
Baker, Darren P. [1 ]
Silvian, Laura F. [1 ]
机构
[1] Biogen Idec Inc, Cambridge Ctr 12, Drug Discovery Dept, Cambridge, MA 02142 USA
[2] Biogen Idec Inc, San Diego, CA 92122 USA
[3] Sunesis Pharmaceut Inc, San Francisco, CA 94080 USA
关键词
Bruton's tyrosine kinase; BTK; Dasatinib; Celera compound; TEC-family; crystal structure; X-LINKED AGAMMAGLOBULINEMIA; CRYSTAL-STRUCTURES; SELECTIVE INHIBITORS; POTENT INHIBITOR; SRC FAMILY; BTK; LFM-A13; DESIGN; DOMAIN; DASATINIB;
D O I
10.1002/pro.321
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation. Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resolution, ligand-bound BTK structure. Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 angstrom resolution or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin-7-yl-cyclopentane at 1.6 angstrom resolution. This data provides information relevant to the development of small molecule inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases. Analysis of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.
引用
收藏
页码:429 / 439
页数:11
相关论文
共 37 条
  • [21] ANGIOTENSIN-II CAUSES ACTIVATION OF TYROSINE KINASES, MAP KINASES AND S6 KINASE CASCADE VIA CA2+ DEPENDENT MECHANISM IN CARDIAC MYOCYTES
    SADOSHIMA, J
    IZUMO, S
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 232 - 232
  • [22] Sustained activation of Src-family tyrosine kinases by ischemia: A potential mechanism mediating extracellular signal-regulated kinase cascades in hippocampal dentate gyrus
    Guo, J.
    Wu, H. W.
    Hu, G.
    Han, X.
    De, W.
    Sun, Y. J.
    NEUROSCIENCE, 2006, 143 (03) : 827 - 836
  • [23] CD28 IS ASSOCIATED WITH AND INDUCES THE IMMEDIATE TYROSINE PHOSPHORYLATION AND ACTIVATION OF THE TEC FAMILY KINASE ITK/EMT IN THE HUMAN JURKAT LEUKEMIC T-CELL LINE
    AUGUST, A
    GIBSON, S
    KAWAKAMI, Y
    KAWAKAMI, T
    MILLS, GB
    DUPONT, B
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (20) : 9347 - 9351
  • [24] High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma
    Yue, Chenglong
    Niu, Mingshan
    Shan, Qian Qian
    Zhou, Ting
    Tu, Yiming
    Xie, Peng
    Hua, Lei
    Yu, Rutong
    Liu, Xuejiao
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36
  • [25] Rilzabrutinib, a potent and selective Bruton's tyrosine kinase inhibitor, suppresses reactive oxygen species production and CD11b activation in human eosinophils
    Shade, Kai-Ting
    Mukai, Shin
    Hicks, Alexandra
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [26] High expression of Bruton’s tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma
    Chenglong Yue
    Mingshan Niu
    Qian Qian Shan
    Ting Zhou
    Yiming Tu
    Peng Xie
    Lei Hua
    Rutong Yu
    Xuejiao Liu
    Journal of Experimental & Clinical Cancer Research, 36
  • [27] Bruton's tyrosine kinase mediates NF-κB activation and B cell survival by B cell-activating factor receptor of the TNF-R family
    Shinners, Nicholas P.
    Carlesso, Gianlllca
    Castro, Iris
    Hoek, Kristen L.
    Corn, Radiah A.
    Woodland, Robert L.
    Scott, Martin L.
    Wang, Demin
    Khan, Wasif N.
    JOURNAL OF IMMUNOLOGY, 2007, 179 (06): : 3872 - 3880
  • [28] Fenebrutinib, a noncovalent, reversible, Bruton's tyrosine kinase inhibitor, potently blocks neuroinflammation induced by Fcy receptor activation in human microglial systems: implications for multiple sclerosis treatment
    Langlois, Julie
    Lange, Simona
    DeGeer, Jonathan
    Macnair, Will
    Harp, Christopher
    Shen, Yun-An
    Collin, Ludovic
    Nicholas, Jacqueline
    Oh, Jiwon
    Keaney, James
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 593 - 594
  • [29] The tumor suppressor PAG1 controls the localization of active SRC family kinases to late endosomes and determines cell fate decisions downstream of receptor tyrosine kinase activation.
    Foltz, L. E.
    Palacios-Moreno, J.
    Mayfield, M.
    Kinch, S.
    Syrenne, J.
    Grimes, M. L.
    MOLECULAR BIOLOGY OF THE CELL, 2018, 29 (26)
  • [30] Activation of phospholipase C-Y2 mutants mediating ibruntinib resistance in human chronic lymphocytic leukemia cells by non-catalytic functions of Bruton's tyrosine kinase
    Wist, M.
    Haas, J.
    Meier, L.
    Gutman, O.
    Endres, S.
    Roesler, R.
    Wiese, S.
    Henis, Y. I.
    Gierschik, P.
    Walliser, C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2020, 393 (SUPPL 1) : 5 - 5